The European Validation Authority for Alternatives to Animal Experiments (EURL ECVAM) is currently conducting a survey on acceptance and confidence in animal-free methods such as 3D cell cultures, spheroids, bioreactor models and microphysiological systems.

Recently, the European Pharmacopoeia Commission decided to discontinue the use of animals during batch testing for abnomal toxicity (ATT) of diphteria sera.

Newsletter April 2018

Thursday, 19 April 2018 19:03

On April 17, Dr Alexander Mosig from the University Hospital Jena presented his current research project, a intestine-liver sepsis model on the chip, to young scientists at the Technical University Berlin.

In its first issue of a new series "Replacement of the Year", the German Animal Rights Organisation People for Animal Rights Germany (PARG) criticises the stalling implementation of new methods to replace animal organ consumption in cardiotoxicity testing.

Virginia is the fourth state to adopt a House Bill (No. 1087), which requires manufacturers or test contractors to use recognized alternatives to animal testing on chemicals, household products and cosmetics.

EPA has released a draft strategy to reduce the use of vertebrate animals in chemical testing for public comment.

An expert group consisting of the Joint Research Center of the European Commission, regulators, scientists and industry representatives recently discussed the further approach in nanotoxicology and the possibilities of using alternative methods to animal testing to assess their effectiveness.

The JRC has commissioned a study to review available educational and training resources to support the 3Rs approach. The aim of the study is to provide an initial overview of education and training opportunities at school, university and professional level.

From the 27th to 29th August, the 12th International Congress and Workshops on Biological Barriers will take place at the Helmholtz Centre for Pharmaceutical Research Saarland (HIPS) at Saarland University in Saarbrücken. In the focus of Biological Barriers are human cell and tissue models for facilitating clinical translation of new drugs and delivery systems, especially in the context of infectious diseases.